Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development
22 Gennaio 2025 - 2:00PM
Business Wire
- Robert Blaustein, M.D., Ph.D. appointed as
Chief Development Officer (CDO) -
- Behrad Derakhshan, Ph.D. promoted to Chief
Operating Officer (COO) -
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle
disease biopharmaceutical company, today announced key changes to
its executive team that will strengthen its leadership and sharpen
the Company’s focus on late-stage clinical development. These
changes include the addition of Robert Blaustein, M.D., Ph.D.,
joining the Company as Chief Development Officer and the promotion
of Behrad Derakhshan, Ph.D. from Chief Business Officer to Chief
Operating Officer.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20250122879951/en/
Robert Blaustein, M.D., Ph.D., Chief
Development Officer, Edgewise Therapeutics (Photo: Business
Wire)
"These leadership changes signify our organization's progression
into late-stage clinical development, setting the stage for the
future commercialization of our novel therapeutics," said Kevin
Koch, Ph.D., President and Chief Executive Officer of Edgewise
Therapeutics. "As we welcome Rob, it’s an exciting time for the
Company, and we are fortunate to have a highly experienced
executive team guiding us forward."
Robert Blaustein, M.D., Ph.D., joins the Company as Chief
Development Officer, responsible for leading EDG-7500, a novel
cardiac sarcomere modulator in Phase 2 development, as well as the
cardiovascular and cardiometabolic pipeline. With significant depth
of experience in cardiovascular drug development, Dr. Blaustein
joins from Merck where he was most recently Associate Vice
President and the Atherosclerosis Section Head in the
Atherosclerosis and Metabolism Clinical Research Department,
leading all late phase development efforts in this area. During his
15+ years at Merck, Dr. Blaustein contributed to clinical programs
across a range of cardiovascular targets and led clinical
development in the atherosclerosis and heart failure spaces.
Importantly, he led the vericiguat development team through the
completion of the Phase 3 VICTORIA heart failure trial, subsequent
regulatory filing and global approval of vericiguat for the
treatment of patients with worsening heart failure, a collaborative
effort with Bayer AG. Dr. Blaustein obtained his undergraduate
degree in mathematics from Wesleyan University. His post-graduate
training included medical residency at Brigham and Women’s
Hospital, cardiology fellowship at Massachusetts General Hospital,
and an HHMI post-doctoral fellowship in the Biochemistry Department
at Brandeis University. He subsequently served on the faculty of
Tufts Medical Center prior to joining Merck.
Dr. Semigran, current CDO, will depart from the Company and will
serve as a clinical advisor for a period to ensure a smooth
transition. “On behalf of the Board of Directors and the entire
Edgewise organization, I want to thank Marc for his leadership and
contributions to our cardiovascular program,” said Dr. Koch. "Marc
played a prominent role in successfully advancing EDG-7500 in the
clinic.” Most recently the Company reported positive topline data
of EDG-7500 in the Phase 1 trial in healthy subjects and from the
single-dose arm (part A) of the Phase 2 CIRRUS-HCM trial in
patients with obstructive hypertrophic cardiomyopathy (HCM).
Further, the Company opened and began enrolling the 28-day arms
(parts B and C) and the 12-week open label extension (part D) of
the CIRRUS-HCM trial in patients with obstructive HCM and
non-obstructive HCM. There are no changes in previously described
milestone timelines for the Company’s cardiovascular program.
Behrad Derakhshan, Ph.D., joined Edgewise in 2020 as Chief
Business Officer, leading the Company’s efforts in strategic
planning, business development, capital formation, investor
relations, corporate communications and commercial planning. He was
instrumental through the Company’s highly successful initial public
offering, played a key role securing several additional funding
rounds and driving the strategic direction of the organization. Dr.
Derakhshan’s leadership and vision have been instrumental in
fueling Edgewise’s growth and success to date. As COO, Dr.
Derakhshan will be responsible for enabling the operational
readiness of the organization as the Company approaches significant
milestones in the muscular dystrophy and cardiovascular programs,
moving toward a commercial-ready biopharmaceutical company.
These changes to the Edgewise executive team are effective
immediately.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease
biopharmaceutical company developing novel therapeutics for
muscular dystrophies and serious cardiac conditions. The Company’s
deep expertise in muscle physiology is driving a new generation of
novel therapeutics. Sevasemten is an orally administered
first-in-class fast skeletal myosin inhibitor in late-stage
clinical trials in Becker and Duchenne muscular dystrophies.
EDG-7500 is a novel cardiac sarcomere modulator for the treatment
of hypertrophic cardiomyopathy and other diseases of diastolic
dysfunction, currently in Phase 2 clinical development. The entire
team at Edgewise is dedicated to our mission: changing the lives of
patients and families affected by serious muscle diseases. To learn
more, go to: www.edgewisetx.com or follow us on LinkedIn, X ,
Facebook and Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250122879951/en/
Edgewise Contacts Investors: Michael Carruthers,
Chief Financial Officer ir@edgewisetx.com
Media: Maureen Franco, VP Corporate Communications
media@edgewisetx.com
Grafico Azioni Edgewise Therapeutics (NASDAQ:EWTX)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Edgewise Therapeutics (NASDAQ:EWTX)
Storico
Da Feb 2024 a Feb 2025
